Defence Therapeutics: Revolutionizing Immune-Related Therapies with ACCUM Technology
Defence Therapeutics is a Canadian biotech company developing immune-related therapies using their proprietary ACCUM technology.
Investing in healthcare
Defence Therapeutics is a Canadian biotech company developing immune-related therapies using their proprietary ACCUM technology. The technology helps bio drugs overcome intracellular barriers, making them more effective. Defence is excited about three upcoming clinical trials, expected to start by the end of the year, which will be important for the company's growth. Defence is also actively working to license their technology to other companies. The mRNA therapeutics market is projected to reach close to $130 billion by 2030, making the potential for Defence's growth promising.
For more information on Defence Therapeutics Inc. (CSE: DTC, OTC: DTCFF) please click the request investor info button.
Latest Articles
Hot Companies
You might also like
BTV Showcases Contango Ore, Critical Elements Lithium, Dryden Gold, FireFox Gold, Kirkland Lake, Klondike Gold, and Selkirk Mines
This week, BTV - Business Television we feature growth-focused mining companies advancing major projects across North America and Europe. From emerging producers and strategic combinations to high-grade exploration and critical mineral development, this episode highlights the next wave of opportunity in the resource sector, including:
Selkirk Copper: A Yukon restart positioned to deliver new Canadian copper supply by 2028
A 50,000-metre drill program began last summer to expand understanding of the resource and guide updated mine design. The goal is to define a 12–15 year mine life while refreshing permits and engineering.
